Skip to content

Botox Injection for Lower Extremity Lengthening and Deformity Correction Surgery

Safety and Efficacy of Botox Injection in Alleviating Post-Operative Pain and Improving Quality of Life in Lower Extremity Limb Lengthening and Deformity Correction

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00412035
Acronym
BOLLD
Enrollment
125
Registered
2006-12-15
Start date
2007-01-31
Completion date
2012-12-31
Last updated
2014-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unequal Length of Limbs; Congenital, Lower Extremity Deformities, Congenital

Brief summary

The purpose of this six site multi-center study is to determine if BTX-A can alleviate the post-operative pain and improve the functional and quality of life outcomes of children with limb length discrepancy or angular deformity undergoing limb lengthening or deformity correction.

Detailed description

The specific aims are to determine if BTX-A will: * 1a. Reduce pain post operatively and during the distraction and consolidation process, * 1b. Reduce the amount, frequency and duration of narcotics taken in the postoperative period. * 2\. Improve the quality of life during the distraction and consolidation process. * 3 Decrease muscular spasm and subsequent muscle contracture during the distraction and consolidation process and accelerate earlier return to pre-operative mobility function including earlier weight bearing. * 4\. To develop clinical practice guidelines for the interdisciplinary care of children undergoing limb lengthening or deformity correction. Methodology: A randomization process for this one time injection will be used to determine who will receive the BTX-A or the placebo. 150 subjects will be recruited; 75 to the BTX-A group and 75 to the placebo group. There will be an equal number of subjects in each group at each site. The medication will be injected intraoperatively into specific major muscles in the lower limb adjacent to the bone or soft tissue being lengthened or corrected at a dose of 10 U/kg with a maximum of 50 U per site, not to exceed a total maximum dose of 400 units. Pain scores, medication dosages, range of motion and an ambulation scale will be measured post-operatively and during the distraction and consolidation phases. In addition families will be asked to complete six different questionnaires related to pain, quality of life and psycho-social issues at various times during the process. The children will receive standard nursing care and physical therapy and will be followed for three months after the external fixator is removed, for a total time of approximately one year.

Interventions

10 units per kilo to maximum of 400 units

DRUGsaline injection

10 units per kilo to maximum of 400 units

Sponsors

Shriners Hospitals for Children
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
5 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

* Age: 5 to 21 years. * Aetiology of the deformity: congenital or acquired. * Amount of lengthening or deformity correction: any amount. * Site of lengthening or deformity correction: lower extremity. * Type of fixator: circular or uniplanar.

Exclusion criteria

* Children younger than 5 years of age. * Associated neuromuscular conditions that may hinder weight bearing. * Individuals on aminoglycosides, as aminoglycosides can potentiate the effect of Botulinum toxin A.

Design outcomes

Primary

MeasureTime frame
average pain scores in 1st 4 days post op1st 4 days post op
total amount of narcotic used in 1st 4 days post op1st 4 days post op

Secondary

MeasureTime frame
Quality of life (PedsQL)pre-op, mid distractionm end distraction, pre frame removal, 3 months post frame removal
Active and passive range of motionpre-op, mid distractionm end distraction, pre frame removal, 3 months post frame removal
Muscle strengthpre-op, mid distractionm end distraction, pre frame removal, 3 months post frame removal
Ambulation scores (FAQ)pre-op, mid distractionm end distraction, pre frame removal, 3 months post frame removal

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 6, 2026